Vaccinations to Start at End of January 2021
The Indonesian Food and Drug Monitoring Agency, predicts that it will authorize the emergency use of China’s Sinovac COVID-19 candidate vaccine, at the end of January 2021.
This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna. - Moderna on November 16, 2020 announced its experimental vaccine against Covid-19 was almost 95 percent effective, marking a second major breakthrough in the quest to end the pandemic.
JAKARTA, KOMPAS – The Indonesian Food and Drug Monitoring Agency (BPOM) predicts that it will authorize the emergency use of China’s Sinovac COVID-19 candidate vaccine, which is currently undergoing clinical trials in Indonesia, at the end of January 2021. This is because data from the final stage of trials will only be submitted to the BPOM in the second week of January. The data is required to ensure the quality, safety and effectiveness of the vaccine.
BPOM chief Penny K. Lukito said on Thursday (19/11/2020) in Jakarta that the emergency use of the candidate vaccine could only be authorized once the data on its quality, safety and effectiveness was complete. Data on the Sinovac candidate vaccine and the results of its clinical trials in Indonesia, Brazil and China are not yet available.